Reports Q4 revenue $13.799M, consensus $7.52M. “Following our PROSERA topline results, we are focused on fully understanding the PROSERA dataset, engaging with the FDA, and evaluating strategic options and capital allocation to position the Company for the future,” said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio (GOSS). “PROSERA narrowly missed the prespecified statistical threshold for its primary endpoint; however, we believe the totality of evidence supports that seralutinib is an active drug in PAH, with the most pronounced effects observed in patients with more advanced disease.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOSS:
- Stagflation Risk Is Back — These 3 Stocks Can Help Defend Your Portfolio
- Gossamer Bio options imply 46.1% move in share price post-earnings
- GOSS Upcoming Earnings Report: What to Expect?
- Gossamer Bio price target lowered to $5 from $10 at H.C. Wainwright
- Gossamer Bio price target lowered to $3 from $12 at Oppenheimer